<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="27810">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02744677</url>
  </required_header>
  <id_info>
    <org_study_id>2015-01</org_study_id>
    <nct_id>NCT02744677</nct_id>
  </id_info>
  <brief_title>COMPASSION S3 - Evaluation of the SAPIEN 3 Transcatheter Heart Valve in Patients With Pulmonary Valve Dysfunction</brief_title>
  <official_title>COngenital Multicenter Trial of Pulmonic vAlve Dysfunction Studying the SAPIEN 3 interventIONal THV</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Edwards Lifesciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Edwards Lifesciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>No</is_unapproved_device>
    <is_ppsd>No</is_ppsd>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the hypothesis that valve dysfunction of the
      Edwards Lifesciences SAPIEN 3 Transcatheter Heart Valve (THV) System is within the
      performance goal of 25% in subjects with a dysfunctional right ventricular outflow tract
      (RVOT) conduit with a clinical indication for intervention.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to demonstrate the safety and effectiveness of the Edwards
      Lifesciences SAPIEN 3 THV System in subjects with a dysfunctional RVOT conduit with a
      clinical indication for intervention.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 2016</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>THV dysfunction, defined as a non-hierarchical composite of: RVOT reintervention, Moderate or greater total pulmonary regurgitation (PR) via Transthoracic Echocardiography (TTE), Mean RVOT gradient &gt; 40 mmHg via TTE</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Device Success</measure>
    <time_frame>Immediately post-procedure</time_frame>
    <description>Defined as a composite of: 1) Single THV implanted in the desired location, 2) RV-PA peak-to-peak gradient &lt; 35 mmHg post-implantation, 3) Less than moderate PR by discharge TTE (or earliest evaluable TTE), 4) Free of explant at 24 hours post-implantation.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">58</enrollment>
  <condition>Complex Congenital Heart Defect</condition>
  <condition>Dysfunctional RVOT Conduits</condition>
  <arm_group>
    <arm_group_label>TPVI</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Transcatheter Pulmonary Valve Implantation with the SAPIEN 3 THV</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>SAPIEN 3 THV</intervention_name>
    <description>SAPIEN 3 THV in the pulmonic position</description>
    <arm_group_label>TPVI</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Weight ≥ 20 kg (44 lbs.)

          -  RVOT conduit with a landing zone diameter ≥ 18 mm and ≤ 29 mm immediately prior to
             study device insertion

          -  Subject presents with at least moderate PR and/or mean RVOT gradient ≥ 35 mmHg.

          -  The subject/subject's legally authorized representative has been informed of the
             nature of the study, agrees to its provisions and has provided written informed
             consent.

        Exclusion Criteria:

          -  RVOT with dysfunctional, previously implanted pulmonary valve (either surgical or
             transcatheter valve)

          -  Active infection requiring current antibiotic therapy (if temporary illness, subject
             may be a candidate 2 weeks after discontinuation of antibiotics)

          -  History of or active endocarditis (active treatment with antibiotics) within the past
             180 days

          -  Leukopenia (WBC &lt; 2000 cells/µL), anemia (Hgb &lt; 7 g/dL), thrombocytopenia (Platelets
             &lt; 50,000 cells/µL) or any known blood clotting disorder

          -  Inappropriate anatomy for femoral introduction and delivery of the SAPIEN 3 THV
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>D. Scott Lim, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Virginia Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Vasilis Babaliaros, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Emory University Hospitals</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sara Scrivano</last_name>
    <phone>949 250 5965</phone>
    <email>Sara_Scrivano@Edwards.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Tenley Koepnick</last_name>
    <phone>949-250-6504</phone>
    <email>Tenley_Koepnick@Edwards.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Ronald Reagan UCLA Medical Center/Mattel Children's Hospital</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniel S Levi, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>UCSF Medical Center</name>
      <address>
        <city>San Fransisco</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Vaikom S Mahadevan, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Emory University School of Medicine/Children's Healthcare of Atlanta</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vasilis C Babaliaros, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Christ Hospital/University of Kentucky</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40506</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dean J. Kereiakes, FACC, FSCAI</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Washington University Barnes-Jewish Hospital/St. Louis Children's Hospital</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alan Zajarias, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center/New York - Presbyterian Morgan Stanley Children's Hospital</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert J Sommer, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gregory A Fleming, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Penn Presbyterian Medical Center, University of Pennsylvania/ Children's Hospital of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wilson Y Szeto, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Intermountain Medical Center/Primary Children's Hospital, University of Utah</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84157</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brian K Whisenant, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Virginia</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22908</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>D Scott Lim, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Washington/Seattle Children's Hospital</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mark Reisman, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <lastchanged_date>February 6, 2017</lastchanged_date>
  <firstreceived_date>April 12, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Tetralogy of Fallot</keyword>
  <keyword>Aortic Valve Defect/Disease Resulting in Ross Procedure</keyword>
  <keyword>Pulmonary Atresia</keyword>
  <keyword>Pulmonary Stenosis</keyword>
  <keyword>Truncus Arteriosus</keyword>
  <keyword>Transposition of the Great Arteries</keyword>
  <keyword>Transcatheter pulmonary valve implantation</keyword>
  <keyword>Transcatheter pulmonary valve replacement</keyword>
  <keyword>TPV</keyword>
  <keyword>TPVR</keyword>
  <keyword>TPVI</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Heart Defects, Congenital</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
